Cytori Cell Research Institute (TSE:3750) Debt-to-Equity : 3.70 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Cytori Cell Research Institute Debt-to-Equity?

Cytori Cell Research Institute's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円919 Mil. Cytori Cell Research Institute's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円6,843 Mil. Cytori Cell Research Institute's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円2,100 Mil. Cytori Cell Research Institute's debt to equity for the quarter that ended in Dec. 2023 was 3.70.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cytori Cell Research Institute's Debt-to-Equity or its related term are showing as below:

TSE:3750' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 1.73 Max: 3.81
Current: 3.7

During the past 13 years, the highest Debt-to-Equity Ratio of Cytori Cell Research Institute was 3.81. The lowest was 0.06. And the median was 1.73.

TSE:3750's Debt-to-Equity is ranked worse than
96.98% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSE:3750: 3.70

Cytori Cell Research Institute Debt-to-Equity Historical Data

The historical data trend for Cytori Cell Research Institute's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytori Cell Research Institute Debt-to-Equity Chart

Cytori Cell Research Institute Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.91

2.30

2.41

2.50

3.21

Cytori Cell Research Institute Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															2.71	3.21	3.38	3.81	3.70

Competitive Comparison of Cytori Cell Research Institute's Debt-to-Equity

For the Biotechnology subindustry, Cytori Cell Research Institute's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytori Cell Research Institute's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytori Cell Research Institute's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cytori Cell Research Institute's Debt-to-Equity falls into.

Cytori Cell Research Institute Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cytori Cell Research Institute's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(901.237	+	7605.855)	/	2652.674
	=	3.21

Cytori Cell Research Institute's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(918.765	+	6843.099)	/	2100.001
	=	3.70

Cytori Cell Research Institute (TSE:3750) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cytori Cell Research Institute Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cytori Cell Research Institute's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytori Cell Research Institute (TSE:3750) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytori Cell Research Institute Inc (TSE:3750) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004

Website

https://www.cytori.co.jp

Cytori Cell Research Institute Inc developing a new clinical approach to cell therapy to provide better medical care to patients by providing medical care that responds to unmet medical needs based on innovative regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.

Cytori Cell Research Institute (TSE:3750) Headlines

No Headlines